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Bioluminescent imagingThe advances in microscopy combined to the invaluable progress carried by the utilization of molecular,
immunological or immunochemical markers and the implementation of more powerful imaging technologies
have yielded great improvements to the knowledge of the interaction between microorganisms and their
hosts, notably a better understanding of the establishment of infectious processes. Still today, the intricacies of
the dialog between parasites, cells and tissues remain limited. Some improvements have been attained with
the stable integration and expression of the green ﬂuorescence protein or ﬁreﬂy luciferase and other reporter
genes, which have allowed to better approach the monitoring of gene expression and protein localization
in vivo, in situ and in real time. Aiming at better exploring the well-established models of murine infections
with the characterized strains of Trypanosoma cruzi and Trypanosoma vivax, we revisited in the present report
the state of the art about the tools for the imaging of Trypanosomatids in vitro and in vivo and show the latest
transgenic parasites that we have engineered in our laboratory using conventional transfection methods. The
targeting of trypanosomes presented in this study is a promising tool for approaching the biology of parasite
interactions with host cells, the progression of the diseases they trigger and the screening of new drugs in vivo
or in vitro.
© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Neglected diseases have gained particular attention from the eco-
nomic powers these last years. These diseases are caused by parasites,
bacteria or viruses considered until recently as those whose research
support is very limited in comparisonwith the immense burden the dis-
eases they cause, pose to humanity [1]. Today, one-sixth of the world's
population suffers from at least one of these pathologies, as stated by
the Global Health Observatory from the World Health Organization.
They are not a “market” attractive to stimulate the large pharmaceutical
companies in research and development (R&D) of new therapies. Not
long ago, some efforts have revived the interest of pharmaceutical com-
panies for “neglected” diseases, mainly targeting malaria, tuberculosis
and AIDS (Acquired Immunodeﬁciency Syndrome). Since these three
diseases are present in rich countries or affect travelers, these efforts33 1 4061 3185.
io).
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between the public and private sectors. Unfortunately, this strategy
has little impact on what is now described as the “most neglected
diseases” such as those caused by parasites from the Trypanosomatidae
family comprising Human and Animal trypanosomosis, leishmaniosis
and Chagas Disease. The socio-economic impact of these diseases is
very considerable, even if it tends to decrease in response to advances
in the ﬁght against insect vectors. The increased knowledge of cell
biology and of the metabolic pathways of these trypanosomatids,
as well as amore detailed knowledge of the interaction of these parasites
with their hosts may carry new rational approaches to improve existing
chemotherapies. In addition, the discovery of new chemotherapeutic
targets against these microorganisms is a major goal of the Millennium
that relies on the setting up of better and reliable medium and high
throughput drug screening assays.
Some improvements to these goals have been anticipated in this last
decade from the techniques of transfection developed for parasites using
several reporter genes. For instance, they have highly contributed for the
understanding ofmany crucial steps of the biology of themicroorganisms
and their relationshipwith their hosts at cellular and tissue levels. Pioneer
studies on the expression of foreign intracellular reporter genes by
trypanosomatids date back to the 90s. Early successful attempts started
in 1991 with the transient expression of β-galactosidase (β-gal) and β-
glucuronidase as reporter enzymes in Leishmania (L.) tropica [2]. The
consideration of glycosome biogenesis to approach the energy source in
trypanosomeswas ﬁrst studied in 1992 by the stable expression of ﬁreﬂy-ND license.
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were followed by others using episomal or stable expression of other
enzymes or green ﬂuorescent protein (GFP) genes, to tackle gene expres-
sion and protein targeting in Leishmania major and Trypanosoma cruzi
[4,5]. These reporter genes have been progressively used since then be-
cause they are sensitive, inexpensive, present low toxicity, and they are
not expressed by mammalian cells. One of the best advantages of the
utilization of transformed parasites with these genes is that they do not
require any ﬁxation and most of them allow an easy imaging in vitro
and in vivo. For instance, different strains of T. cruziwere later transfected
with an integrative vector that allows the expression of GFP or red
ﬂuorescent protein (RFP) showing the usefulness of these mutants
to study several aspects of the infection such as the mechanisms of
cell invasion, of genetic exchange and the differential tissue distribution
in animal models [6]. These studies were followed by those using
trypomastigote and amastigote forms of T. cruzi expressing the luciferase
(luc) reporter gene illustrating the advantages of bioluminescent
parasites for the imaging in vitro and in vivo [7]. The disease progression
of experimental Human African Trypanosomosis and the systemic
tropism, particular to the brain, were subsequently demonstrated by
bioluminescent imaging using mouse adapted strains of Trypanosoma
brucei gambiense [8]. Our recent studieswithmetacyclic trypomastigote
forms of Trypanosoma vivax expressing luciferase have reinforced the
presence of the parasite in the central nervous system ofmice and conse-
quently the brain commitment in the very late phases of the experimen-
tal infection [9]. Other colleagues, using intravital brain imaging and
Trypanosoma brucei brucei or Trypanosoma brucei rhodesiense parasites,
respectively expressing mOrange and tdTomato, have equally re-
ported that human trypanosomes can invade the murine brain
parenchyma during the early stages of infection before meningoen-
cephalitis is fully established [10]. Interestingly, T. b. brucei expressing
luciferase has allowed the determination of the commitment and
dissemination of the parasites to the testis observation that may
hamper the efﬁcacy of treatments for sleeping sickness [11].
Other advances have been reported about the utilization of reporter
genes in protozoan parasites for the discovery and development of new
drugs and of the in vivo imaging for noninvasive visualization of
biological processes (see [12] for a review). Some examples include
the efﬁcacy of drug screening based on the use of GFP-expressing
L. major or Leishmania donovani [13,14], EGFP-, β-gal- or luc-expressing
Leishmania amazonensis [15,16] and more recently on T. cruzi expressing
the tomato protein [17]. In the present work we report some of the
new tools we have developed in our laboratory to the well characterized
strains of T. cruzi (CL and Y) and T. vivax (ILRAD 1392), aiming at better
exploring their infectious process at cellular and tissue levels and to
evaluate the effects of new therapeutic compounds in vitro and in vivo.2. Material and methods
2.1. Mice and ethics
Seven to ten week-old male Swiss Outbred mice (CD-1, RJOrl:
SWISS) (Janvier, France) were used in all experiments. All mice wereTable 1
Plasmid characteristics.
Plasmid Species Size
(bp)
Promoter 5′UTR trans-splicing reg
pTvLrDNA-luc [20] T. vivax 8390 18S r DNAa TvPRAC
pTvLrDNA-crim T. vivax 7197 18S r DNAa TvPRAC
pTcTREX-crim T. cruzi 6929 18S r DNAb HX1-TcP2β
pTcTREX-luc T. cruzi 8164 18S r DNAb HX1-TcP2β
pTcTREX-gfp [25] T. cruzi 7027 18S r DNAb HX1-TcP2β
a 1.8 kb fragment upstream the 18S rDNA of T. vivax.
b 0.8 kb fragment upstream the 18S rDNA of T. cruzi.housed in our animal care facility in compliance with European animal
welfare regulations. Institut Pasteur is a member of Committee #1
of the Comité Régional d'Ethique pour l'Expérimentation Animale
(CREEA), Ile de France. Animal housing conditions and the procedures
used in the work described herein were approved by the “Direction
des Transports et de la Protection du Public, Sous-Direction de la Protec-
tion Sanitaire et de l'Environnement, Police Sanitaire des Animaux”
under number B 75-15-28, in accordance with the Ethics Charter of
animal experimentation that includes appropriate procedures to mini-
mize pain and animal suffering. PM is authorized to perform experiments
on vertebrate animals (license #75-846 issued by the Paris Department
of Veterinary Services, DDSV) and is responsible for all the experiments
conducted personally or under her supervision as governed by the laws
and regulations relating to the protection of animals. All animal work
was conducted in accordance with relevant national and international
guidelines.
2.2. Parasite strains and cell cultures
T. (Dutonella) vivax IL 1392 was originally derived from the Zaria
Y486 Nigerian isolate [18]. These parasites have recently been charac-
terized and are maintained in the laboratory by continuous passages
in mice, as previously described in detail [19,20]. For in vivo experi-
ments, mice were injected intra-peritoneally or sub-cutaneously with
bloodstream forms of T. vivax (102 parasites/mouse). Parasitemia was
determined, as previously described [19]. Cell culture-derived or axenic
amastigote and trypomastigote forms from T. cruzi CL Brener (clone
F11–F5) (www.dbbm.ﬁocruz.br/TcruziDB/clbrener.html) and Y strains
were isolated from the supernatant of bulk cultures of green monkey
Vero kidney cells previously infectedwith bloodstream trypomastigotes
[21]. Epimastigote forms of T. cruzi are maintained by serial passages
in vitro, as previously described [22]. Normal or infected Vero cell
cultures were seeded in microplates or in ﬂasks at 5 × 104 cells/ml in
RPMI 1640 medium/5% FCS and kept at 37 °C, 5% CO2.
T. vivaxmetacyclics were puriﬁed from epimastigote axenic culture
according to [23] with minor modiﬁcations. Normal goat serum was
added to culture supernatants to a ﬁnal concentration of 10% and incu-
bated for 30 min at 27 °C. During the incubation period, epimastigotes
aggregated and formed clumps, while metacyclics remained swimming
freely. The metacyclics were then separated from the epimastigote
clumps by differential centrifugation using a swing out rotor (Jouan
GR412, Fisher Bioblock Scientiﬁc, Strasbourg, France) for 5 min 200 g.
2.3. Vectors and transgenic parasites
The nourseothricin resistance gene (SAT) was ampliﬁed from
pFX4.1SAT (Jena Bioscience) with the primers SAT-forward (5′ ATGGC
GCGCCATGAAGATTTCGGTGATCC 3′) and SAT-reverse (5′ CGCCATGGTT
AGGCGTCATCCTGTGCTCC 3′). The fragment obtained (539 bp) was
digested with AscI and NcoI and inserted into AscI and NcoI sites of
the pTvLrDNA-luc vector [20] to replace the neomycin resistance
gene to obtain pTvLrDNA-luc-SAT (see Table 1). The gene encoding
the near infrared ﬂuorescent protein E2-Crimson [24], was ampliﬁedion Reporter gene Intergenic region Selectable marker 3′ UTR
Luciferase αβ-tub Sat βα-tub
Crimson αβ-tub Sat βα-tub
Crimson 5′-gapdh Neo 3′-gapdh
Luciferase 5′-gapdh Neo 3′-gapdh
GFP 5′-gapdh Neo 3′-gapdh
Fig. 1. Proliferation of T. vivax in the hypodermis after sub-cutaneous injection of culture-derived metacyclic parasites. Dorsal view of a representative Outbred mouse injected subcuta-
neously with 5 × 104 puriﬁed metacyclic forms of TvLrDNA-luc parasites. Bioluminescence was measured at days 12 (A) and 13 (B). Color scale to the right of the pictures encodes for
signal intensity (photons/s).
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AAGCTTATGGATAGCACTGAGAACGTC 3′ and 5′ Crim-reverse GCGGG
ATCCCTACTGGAACAGGTGGTGGCG 3′. The obtained fragment (683 bp)
was digested with HindIII and BamHI and inserted into HindIII and
BamHI sites of the pTvLrDNA-luc-SAT to replace the luciferase gene to
generate pTvLrDNA-Crim-SAT or inserted into T. cruzi speciﬁc pTREX
vector [25] digested with HindIII and BamHI to create pTcTREX-Crim.
Fireﬂy luciferase reporter gene was puriﬁed from pGL3 basic vector
(Promega) digested with HindIII and BamHI and inserted into vector
pTREX previously digested with HindIII and BamHI to create pTREX-
luc. All constructions were validated by sequencing or restriction
cartography. The methods used to engineer T. vivax strain that stably
expresses ﬁreﬂy luciferase (TvLrDNA-luc) or E2-Crimson (TvLrDNA-
Crim) have been described elsewhere [20]. Brieﬂy, nourseothricin wasFig. 2. Bloodstream forms of T. vivax transgenic parasites expressing E2-Crimson ﬂuores-
cence. Undiluted (A) or diluted (1/10, B) blood samples from an infected mouse infected
with TvLrDNA-Crimwere examinedwith a FLoid™ Cell Imaging Station (Molecular Probes
Life Technology, France) using phase contrast (left panels) or red ﬂuorescence channel
(right panels).added to the cultures at a ﬁnal concentration of 1 μg/ml to allow
selection of recombinant T. vivax. Similarly, T. cruzi strain that
stably expresses ﬁreﬂy luciferase (TcTREX-luc), GFP (TcTREX-GFP)
or E2-Crimson (TcTREX-Crim) was obtained by classical electropo-
ration according to [26]. Total parasite genomic DNA was prepared
from in vitro cultures with pure link genomic DNA (Invitrogen,
Life Technologies, Villebon sur Yvette). Correct plasmid integrations
were checked by PCR using standard techniques, oligonucleotide pairs
ﬂancking the integration regions and Dream Taq polymerase (Fermentas,
Villebon sur Yvette, France).
2.4. Effects of speciﬁc trypanosomicidal drugs on parasite survival and
multiplication
Growth inhibition of T. vivax epimastigotes was monitored as
follows. 5.105 transgenic epimastigotes expressing the Luciferase or
E2-Crimson were seeded per well, respectively on clear-bottomed or
black- clear-bottomed 96-well microtiter plates (Corning, Life Sciences,
France). Parasites rapidly adhere to the plastic surface and the super-
natant was replaced by fresh growth medium containing different
concentration of speciﬁc trypanosomicidal drugs such as homidium
bromide (Ethidium), hygromycin, neomycin (G418), or benznidazole
and paromomycin, a G418-analog. After 5 days media were discarded
and adherent cellswashed once in PBS in order tominimize background
and tested for luciferase or ﬂuorescence emission as described here
below.
2.5. Luciferase and ﬂuorescence assays in vitro
A luciferase assay kit (Roche Molecular Biochemicals; Mannhein,
Germany) was used to monitor luciferase expression. Serial dilutions
of T. cruzi suspensions or T. vivax adherent cells were resuspended in
150 μl of cell lysis buffer. The lysates were then transferred into white,
96-well microplates (Dynex Technologies, Chantilly, France). Light
emissionwas initiated by adding the luciferin-containing reagent, in ac-
cordance with manufacturer instructions. The plates were immediately
transferred to the luminometer (Berthold XS3 LB960; Thoiry, France)
and light emission was measured for 0.1 s. Luminescence was expressed
in Relative Light Units (RLU). E2-Crimson emitted ﬂuorescence was
Fig. 3. In vitro T. vivax epimastigote inhibition of growth assay induced by trypanocidal drugs
using ﬂuorescent and luminescent parasites. 5 × 105 epimastigotes expressing E2-Crimson
or Luciferase were inoculated per well into 96-well microplates and treated with Ethidium
Bromide (Homidium bromide, EtB), Hygromycin (HYG), Geneticin (G418), or paromomycin
(PAR) at different concentrations in TV3 medium. After 5 days, growth was determined by
ﬂuorescence (open circles) or luciferase (black squares) assay, as a relative percentage of
the untreated strain. The results are the mean of duplicates and representative of two
experiments.
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NC) using the black-clear-bottomed 96-well microtiter plates in the
bottom-reading mode with excitation at 611 nm and emission at
646 nm.2.6. In vivo bioluminescence imaging
Mice were inoculated intraperitoneally with luciferin (D-Luciferin
potassium salt, Xenogen, California), the luciferase substrate, at a dose
of 150 mg/kg before any bioluminescence measurements were made,
as described [9]. They were anaesthetized in a 2.5% isoﬂurane atmo-
sphere (Aerane, Baxter SA, Maurepas, France) for 5 min and kept in
the imaging chamber for analysis. Emitted photons were acquired
for 1 min by a charge couple device (CCD) camera (IVIS Imaging
System Lumina, Caliper, Villepinte, France) set in high-resolution
(medium binning) mode. The analysis was then performed after
deﬁning a region of interest (ROI). Total photons emitted from the
image of each mouse were quantiﬁed using Living Image software
(Xenogen Corporation, Almeda, California), and results were expressed
as number of photons/s/ROI.
2.7. In vitro ﬂuorescence imaging
Extracellular and intracellular ﬂuorescent live parasite cultures were
analyzedwith a system formulticolor ﬂuorescence FLoid™ Cell Imaging
Station (Molecular Probes Life Technology, France) using phase contrast
or ﬂuorescence channels, or by confocal microscopy using a LMS700
(Carl Zeiss, France).
3. Results and discussion
3.1. Going beyond the development of tools to study T. vivax
3.1.1. Multiplication of T. vivax in the hypodermis
With the use of bioluminescence imaging to track microorgan-
isms in vivo it has become possible to quantify in real time the par-
ticularities, the abundance and the magnitude of an infectious
process. For instance, as compared to other animal trypanosomes
(i.e. T. brucei spp. and Trypanosoma congolense) T. vivax has the ability
to be cyclically transmitted by Glossina spp. (tsetse) ﬂies but also by
other biting ﬂies of the Tabanidae andMuscidae families that mechani-
cally transmit the parasite among mammalian hosts. Regardless of
the natural type of transmission (cyclical or mechanical), T. vivax is
inoculated in the subcutaneous tissue and the infective forms join the
bloodstream via the lymphatic system. We have recently constructed
a T. vivax strain which stably expresses ﬁreﬂy luciferase (TvLrDNA-luc)
and that is fully virulent for immunocompetent mice [9]. The usefulness
of real-time biophotonic analysis in the study and monitoring of
the T. vivax infectious process in vivo was shown by tracking the in-
fection dynamics and organ commitment after the inoculation of
mice with TvLrDNA-luc by the intraperitoneal route conventional
used for experimental infections and the subcutaneous route that
closely resembles the cyclic or mechanical infections conveyed by in-
sects. Surprisingly, a longer prepatent period with a more delayed
parasitemia onset was observed in mice injected subcutaneously
with infective bloodstream forms of the TvLrDNA-luc, as compared
to that observed with mice inoculated by the intraperitoneal route.
We show here that the same is observed when the inoculation is
performed with axenic metacyclic forms of TvLrDNA-luc that have dif-
ferentiated in vitro. Therefore, the light emission ofmice inoculated sub-
cutaneously with metacyclic forms of TvLrDNA-luc is conﬁned to the
skin near the inoculation site (Fig. 1). The increase in light emission in
this region and the very circumscribed foci of photons shows that by
this route of infection the parasite multiplication takes place close to
the injection site before the parasites reach the bloodstream. Without
the utilization of TvLrDNA-luc and the noninvasive analysis of infection
in living animals, the development of T. vivax in the skin would remain
hidden from view or would depend on laborious or sophisticated mi-
croscopic exploration and requiring the sacriﬁce of several mice each
day. Our previous studies have also pointed out that the infection causes
a systemic disease and in the long term the parasite attacks the central
Fig. 4. Bioluminescence production by evolutive stages of TcTREX-luc strain. Serial dilutions of TcTREX-luc epimastigotes (black circles), trypomastigote forms (open circles) and
amastigote forms (black diamonds) were measured in vitro for bioluminescent activity expressed in RLU (Relative Light Unit); the results are representative of two independent
experiments.
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early phases and just a few days before death [9].3.1.2. Brighter T. vivax: Validating far red ﬂuorescence for in vitro imaging
and drug screening
We then decided to explore the utility of T. vivax parasites stably
expressing E2-Crimson protein, a protein that was evoked ideally for
in vivo and stem cell applications due to its emission wavelength
(646 nm) and its brightness [24,26]. The protein matures faster,
and has high photostability, high solubility, and low cytotoxicity. Further-
more, the utilization of in vitro and in vivo imaging with ﬂuorescent pro-
teins is convenient over that of microorganisms expressing luciferase
because they can be easily tracked in deep tissues and their detection
does not require the intraperitoneal injection of any substrate to obtain
ameasurable signal. We have thus engineered a T. vivax strain that stably
expresses the E2-Crimson (TvLrDNA-Crim, see Table 1), as described in
theMaterial andmethods. Themetacyclic infective forms of these re-
combinant parasites obtained in vitro maintain their infectivity to
immunocompetent mouse strains and show the same parasitemia
proﬁles over time that result in similar levels of mortality as wild type
or TvLrDNA-luc T. vivax (not shown). The ﬂuorescence of the parasite
was monitored at all life stages of T. vivax by microscopy. As can be
seen in Fig. 2, bloodstream forms of TvLrDNA-Crim show a bright red
ﬂuorescence distributed throughout all the cell body. Parasites have
beenmaintained in vitro and in vivo for more than 3 months and stably
expressing the ﬂuorescence without antibiotic pressure.
To verify the usefulness of TvLrDNA-luc and TvLrDNA-Crim in growth
inhibition drug screening assays different concentrations of several
cytotoxic compounds were added to parasite cultures in microplates
and the luminescence and the ﬂuorescence signal intensities were
measured 5 days later as representative of T. vivax growth compared
to nontreated wells. A dose dependent decrease of both luminescence
and ﬂuorescent signals has been evident as can be seen in Fig. 3A, B
and C, respectively for Homidiumbromide, Hygromycin and Neomycin.
As can be observed, little variation is observed between the two exper-
iments, ﬁgures are highly consistent and produce comparable results
for TvLrDNA-luc and TvLrDNA-Crim. Noteworthy, the incubation of
the parasites with the Paromomycin, an analog of G418 that is very
toxic for Leishmania spp. is only partially effective in killing T. vivax, asFig. 5. Expression of green ﬂuorescent protein by TcTREX-GFP parasites. Epimastigote forms o
Technology, France) using phase contrast (left panels) or green ﬂuorescence (right panels); inse
of TcTREX-GFP parasites were stained with DAPI (right panel)(A); trypomastigote forms of Tc
intracellular amastigotes throughout their release by the host cells. Days post infection (dpi
(d) and 6 (e) dpi. Images were obtained using a FLoid™ Cell Imaging Station (Molecular Probes
(central panels); right panels represent merged pictures.ascertained by the weak relative decrease of the Crimson ﬂuorescence
and the luminescence signals (Fig. 3D). These data suggested that
both transgenic parasites demonstrate the potential to be used in
medium/high throughput assays of anti-T. vivax compounds in vitro.
Experiments in progress aim at evaluating the utility of TvLrDNA-Crim
in vivo and will be a topic for a further study.3.2. Building new outﬁts for T. cruzi
3.2.1. Gaining sensibility with luciferase and ﬂuorescent reporter genes
Our laboratory has been involved for several decades with a
systematic and global in vivo analysis of the infectious process caused
by T. cruzi, mostly with immune activities triggered by the parasite for
a better understanding of all mechanisms involved in infection aiming
at novel therapeutical approaches [27–34]. However, the methods
allowing for the precise detection of the parasite in the blood and in
deep tissues, or else its interaction with host cells were until recently
restricted to the optical microscopic appreciation of the parasite thus
limiting for instance the evaluation of the efﬁcacy of a treatment. To
better study the mechanisms of host cell invasion, tissue distribution
and the action of anti-parasitic compounds, our group and other groups
have generated different strains of transgenic T. cruzi expressing
luciferase or ﬂuorescent reporter genes. For example, to improve
research on the mechanisms involved in the mammalian pathogenesis
or on the T. cruzi distribution inside the insect vector, Brazil and
DM28C bioluminescent strains of T. cruziwere engineered, respectively
using pBluescript (pBS-THT-x-T)- or pTREX- based plasmids [35,36]. On
one hand, while these studies have shown a close correlation between
total bioluminescence signal in the course of mouse infection and
numbers of T. cruzi expressing the luciferase, they have precluded
detailed assessment of the interaction of the parasite with the host at
the cellular level [7]. On the other hand, the strategy revealed that it
was not always possible to correlate the number of epimastigotes and
the luminescence signal observed in the invertebrate Rhodnius prolixus
alive and a more resolutive image of luminescent T. cruzi was only
obtained in dissected insects [37]. However, the potentiality of the
tool to study anti-parasitic compounds in vitrowas clearly determined.
In our laboratory, we have engineered CL-Brener T. cruzi strain that
expresses luciferase, using the integrative hyperexpression pTREXf TcTREX-GFP were examined with a FLoid™ Cell Imaging Station (Molecular Probes Life
rt depicts closer slide views obtainedwith a confocal microscope; nucleus and kinetoplast
TREX-GFP were used to infect Vero cells; cultures were examined daily for the growth of
) are depicted in the left inferior corner of the pictures, as follows 1 (a), 2 (b), 3 (c), 5
Life Technology, France) using phase contrast (left panels) or green ﬂuorescence channel
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Fig. 6. Engineered TcTREX-luc and TcTREX-GFP are validated for drug screening strategies.
Bioluminescence emission of TcTREX-luc infectedVero cells, with increasing Benznidazole
concentrations; the results are expressed inRLUand correspond to arithmeticmeans ±SD
of the means (B). Fluorescence emission of TcTREX-GFP infected Vero cells, with in-
creasing Benznidazole concentrations; the results are expressed in % of ﬂuorescence and
correspond to arithmetic means ± SD of the means.
Fig. 7. Engineering TcTREX-Crim strain for multicolor applications. Epimastigote (left
panel) and trypomastigote (right) forms of Y strain of T. cruzi (A); TcTREX-Crim parasites
were pictured in the presence of human acute monocyte leukemia cell line (THP-1)
stained with green ﬂuorescence cell dye (pKH2) and DAPI, for contrast.
266 S. Goyard et al. / Parasitology International 63 (2014) 260–268vector. The TcTREX-luc parasites (see Table 1), showed strong emission
of relative luciferase signal (RLU) in all life stages and in complete
absence of antibiotic selection, as can be observed in Fig. 4.
To better explore the biochemical and photophysical properties
of ﬂuorescent proteins that can offer increased sensibility intracellu-
larly as compared to luciferase, several trypanosomatids have been
engineered to express GFP, RFP, EGFP, DsRed such as T. brucei,
Trypanosoma rangeli and Leishmania spp., [15,38–40]. Similarly,
we have expanded in the laboratory the CL-Brener strain of T. cruzi
(clone F11F5) expressing GFP [25]. As can be observed in Fig. 5A the
microscopic observation of the recombinant epimastigote forms of the
TcTREX-GFP reveals that the ﬂuorescence emission by the transgenic
parasites is highly homogeneous, as compared to the absence of ﬂuo-
rescence of WT parasites (not shown). Additional experiments using
the infection of Vero cells with metacyclic TcTREX-GFP parasites differ-
entiated in vitro, show that the emission of ﬂuorescence by infected cells
rises throughout cellular infection, accompanying the increasing in
numbers of intracellular parasites, as depicted in Fig. 5B, opening the
way for evaluating the efﬁcacy of new anti-parasitic drugswith a higher
sensibility at the intracellular level.3.2.2. Exploring new imaging tools for drug screening against T. cruzi
in vitro and in vivo
In viewof assessing if TcTREX-luc and TcTREX-GFP parasites could be
used in the in vitro screening of trypanocydal properties of compounds
anti-T. cruzi, we have set up new methods that rely on the analyses of
light or ﬂuorescent signals emitted by the parasites cultured in presence
or in absence of Benznidazole (N-:benzyl-2-nitro-1-imidazol acetamide),
a current medication against Chagas disease, using most accurate
equipments for imaging in microplates, such as the Tecan and FLoid
machines (see Material and methods). As anticipated, increasing
concentrations of Benznidazole added to the culture of Vero cells
infected with TcTREX-luc trigger a progressive decrease of the photon
emission (RLU), which correlates with the reduced cellular parasitism
(Fig. 6A). Likewise, GFP signal proportionally decreases in Vero cell
cultures infected with TcTREX-GFP parasites cultivated with increasing
concentrations of the drug (Fig. 6B). These results validated these
methodologies for future assays aiming at verifying the killing of
intracellular amastigote forms of the parasite by new therapeutic
leads against Chagas' disease previously identiﬁed in the laboratory
[28,41].
An alternative vector, pROCK-Neo was used some years ago to
facilitate the integration of ﬂuorescent reporter genes into the tubulin
locus of the T. cruzi genome resulting in stable transfections that can
be also maintained without drug selection. This vector was previously
used to introduce into several lineages of T. cruzi, the genes of GFP
267S. Goyard et al. / Parasitology International 63 (2014) 260–268(Colombiana, lineage I and JG, lineage II strains) or RFP (Tulahuen,
lineage II and CL- Brener, hybrid strains) [6]. These combined uses
of such parasites expressing two different markers in co-infection
of Vero cells and the successful presence of T. cruzi expressing RFP
and GFP constitute important technical tools to explore more in
deep studies of genetic exchange in T. cruzi. More recently, CL-Brener
transgenic parasites expressing β-Gal [42] or td-Tomato [17] using a
pTREX backbone vector have been used to identify new drugs anti-
T. cruzi. While the evaluation of drug efﬁcacy using β-Gal — expressing
T. cruzi requires the sacriﬁce of the experimental groups of mice for the
analysis of parasitism rate in tissues mechanically disaggregated
ex-vivo, screening assays using td-Tomato-expressing parasites
made possible the analysis of parasite growth in vitro and in vivo.
Thus, relatively low numbers of parasites expressing the td-Tomato
protein are needed to inject the mice in the hind foot pads allowing
the continuous quantiﬁcation of the ﬂuorescence signal over time.
Aiming at improving deep-tissue imaging in vivo we have generated
TcTREX-Crimson parasites (TcTREX-Crim, see Table 1), since both
auto ﬂuorescence and light scattering decrease substantially with
this far-red shifted protein variant, as we observed for T. vivax (see
here above). The ﬁrst T. cruzi (Y) strain, transfected with TcTREX-Crim
vector is now available in the laboratory and has been submitted
to antibiotic pressure and selection in vitro. Preliminary images of
these parasites can be appreciated in Fig. 7. Likewise, T. cruzi of the CL
strain stably expressing both luciferase and GFP reporter genes has
been generated and selected in vitro and in vivo. These TcTREX-Crim
and TcTREX-luc-GFP (TcRoiGlum) parasites will be useful for whole-
body imaging experiments and multicolor applications, for instance
those implicating transgenic mouse lines expressing speciﬁc green
ﬂuorescent cell populations, such as macrophages and neutrophils
[43–45]. Experiments are in progress in this sense.4. Concluding remarks
The progresses of optical microscopy methodologies and in vivo
imaging approaches involve the utilization of new reporter markers
that facilitate multicolor studies of cellular interactions and tissue
commitment by pathogens. One example is the rapid development
of intracellular pathogens bearing new variants of ﬂuorescent tags
enabling a precise differentiation between the microorganism and
other ﬂuorescent markers used to transform host cells by animal
transgenesis. These tools contribute to the advance of less laborious and
highly performing techniques of imaging in vivo to evaluate infectious
process progression or the efﬁcacy of newchemotherapeutic compounds.
In more practical terms, arduous and inaccurate determination
of parasitic burden in the blood of animals treated or untreated with
chemical compounds by optical microscopy is close to be abandoned.
In fact, the technique is presently replaced by the utilization of parasites
expressing ﬂuorescent proteins and can rapidly be counted using auto-
mated microplate assays and versatile image systems thus offering
highly consistent sets of data, speciﬁcally for low parasite loads. On
top of more comfortable analysis and the greater reproducibility they
offer, the expression of luciferase or ﬂuorescent reporter genes has
allowed the setting up ofmedium/high throughput assays for the better
evaluation of the toxicity of anti-parasitic drugs in vivo, tackling the
effectiveness of a compound at deep tissue levels. Moreover, the
efﬁcient usage of parasites expressing ﬂuorescent proteins supports
the dynamic study of the same ongoing culture of parasitized cells for
extended periods of time by using, for instance, an appropriate and
fully integrated system for multicolor ﬂuorescence cell imaging station
like the onewe used in this report. This type of apparatus contrasts with
old-fashioned techniques based on the fastidious counting of stained
cells on ﬁxed slides. It is important to note that these recent strategies
of imaging allow the detection of low numbers of parasites that would
not be noticeable due to the limits of classic optical microscopy.Finally, the novel intracellular applications of ﬂuorescent proteins,
their structure and corresponding functions, as well as the extensive
range of spectroscopic features appropriate for high resolution tech-
niques of imaging have been reviewed recently [46,47]. The versatility,
photostability and, more importantly, the low cytotoxicity and the stable
expression of far-red ﬂuorescent reporter genes have solved some
troublesome questions induced by the classical transgenesis of parasites.
In fact, transfection of parasites may regularly give rise to a lack of viru-
lence that has been explained either by the stress of the transfection
programs used, by the long term maintenance of the mutants in vitro,
or yet by the intrinsic toxicity of the ﬂuorescent protein compromising
the parasite viability in vitro and in vivo. For instance, the E2-Crimson, a
ﬂuorescent derivative of DsRed protein, does not present any toxicity
for mammals and isolated cells and is one the most recent ﬂuorescent
proteins whose utilization is appropriate for imaging of living animals.
Mainly this is due to its excitation and emission wavelengths above
600 nm, which have low absorption and light-scattering in tissues.
This characteristic, associated to the photostability of E2-Crimson makes
this ﬂuorescent protein useful for multicolor analysis of infectious
processes using transgenic cells or tissues expressing other ﬂuorescent
proteins such the GFP or orange ﬂuorochromes. Furthermore, E2-
Crimson is particularly advantageous in combined exploration of data
that rely on the ﬂow cytometry and the two color stimulated emission
depletion (STED) microscopy that enables a super-spatial resolution
of cellular interactions and other dynamic processes of live cells [24,48].
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